AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06118658
Drug: tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
Trial: NCT04660760
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT05233124
Drug: Rivaroxaban 15 MG
RxNorm normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 15mg
Trial: NCT05233124
Drug: Clopidogrel 75 Mg Oral Tablet
RxNorm normalized name: CLOPIDOGREL 75 mg ORAL TABLET
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 75mg
Trial: NCT04596644
Drug: Cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigates two strengths of cannabis.
Trial: NCT00002304
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002304
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04141319
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30ml of local infiltration solution containing 6mg ketorolac
Trial: NCT05958589
Drug: Caudal block with levobupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the introduction of general anesthesia, a single shot caudal block will be performed with levobupivacaine 0.25% (2.5 mg/kg; maximal dose 75 mg).
Trial: NCT05899829
Drug: Camlipixant
RxNorm normalized name: Camlipixant
DrugBank: Camlipixant (DB19217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camlipixant will be administered
Trial: NCT05899829
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole will be administered
Trial: NCT05899829
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin will be administered.
Trial: NCT04516603
Drug: Fampridine SR
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
Trial: NCT06278051
Drug: Rivaroxaban granules for oral suspension
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment dose and period decided by its prescription
Trial: NCT06278051
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment dose and period decided by its prescription
Trial: NCT06176248
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 injection of local anaesthetic (5 ml levobupivacaine 2.5 mg/mL) opposite the subscapular nerve, under ultrasound control, in a lateral decubitus or sitting position. Subsequently, they underwent Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.
Trial: NCT06176248
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intramuscular injection of 1 ml saline under ultrasound control under the same conditions as the experimental group. Subsequently, they will undergo Xray-controlled arthrodistension under the same conditions as the experimental group
Trial: NCT06218979
Drug: Risperidone oral solution
RxNorm normalized name: Risperidone Oral Solution
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: See arm/group descriptions
Trial: NCT05000372
Drug: 68Ga-grazytracer
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.
Trial: NCT05320406
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM or SC
Trial: NCT05320406
Drug: Relugolix
RxNorm normalized name: Relugolix
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06046248
Drug: Belumosudil
RxNorm normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg PO QD x 24 cycles (28-day cycle)
Trial: NCT06046248
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
Trial: NCT06126497
Drug: Ropanicant
RxNorm normalized name: Ropanicant
DrugBank: Ropanicant (DB19134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06163326
Drug: Ritlecitinib
RxNorm normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 50 mg capsule once daily
Trial: NCT06163326
Drug: Ritlecitinib 100 mg
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 100 mg capsule once daily
Trial: NCT00002007
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002007
Drug: Sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04678401
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)
Trial: NCT04678401
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)
Trial: NCT04678401
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)
Trial: NCT06225466
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.
Trial: NCT06225466
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.
Trial: NCT05522738
Drug: Combination: Fruquintinib + FOLFIRI
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1b Fruquintinib was administered in a 3 + 3 dose escalation regimen at the following doses: L1:3 mg/d, L2:4 mg/d, L3:5 mg/d.~Fruquintinib: QD po q2w~FOLFIRI regimen:~Irinotecan：180 mg/m2, i.v. , d1, q2w LV：200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w~Phase II Fruquintinib: RP2D, QD po q2w~FOLFIRI regimen:~Irinotecan： 180 mg/m2, i.v. , d1, q2w LV： 200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w
Trial: NCT06680921
Drug: Everolimus (Afinitor®)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental and Active comparator
Trial: NCT06680921
Drug: Exemestane tablets
RxNorm normalized name: Exemestane Tablets
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT06680921
Drug: Fulvestrant injection
RxNorm normalized name: Fulvestrant Injection
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Active Comparator
Trial: NCT04576494
Drug: Nusinersen
RxNorm normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nusinersen
Trial: NCT04826237
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral dose, standard of care
Trial: NCT04826237
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug for intratympanic administration
Trial: NCT06389214
Drug: Reproxalap Ophthalmic Solution (0.25%)
RxNorm normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
Trial: NCT06389214
Drug: Vehicle Ophthalmic Solution
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution administered six times over two consecutive days
Trial: NCT05651633
Drug: lidocaine hydrochloride 5mg/g
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-2 drops up to six times daily for a maximum of 7 days
Trial: NCT04707092
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week
Trial: NCT05079360
Drug: Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
Trial: NCT05162690
Drug: Dapagliflozin 10 milligram
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg per day of Dapagliflozin will be given to the patients
Trial: NCT05187793
Drug: Olokizumab
RxNorm normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
Trial: NCT05275673
Drug: sapanisertib
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules for oral administration
Trial: NCT06199232
Drug: HAIC+targeted therapy+PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w.
Trial: NCT04753619
Drug: Niclosamide Oral Tablet
RxNorm normalized name: niclosamide Oral Tablet
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\]~* If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
Trial: NCT05122546
Drug: Cabozantinib S-malate
RxNorm normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05122546
Drug: Clostridium butyricum CBM 588 Probiotic Strain
RxNorm normalized name: Clostridium tetani
DrugBank: Clostridium tetani (DB09876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05720455
Drug: Fexofenadine HCL and pseudoephedrine HCL
RxNorm normalized name: FEXOFENADINE HYDROCHLORIDE 180 mg / PSEUDOEPHEDRINE HYDROCHLORIDE 240 mg ORAL TABLET, EXTENDED RELEASE [Fexofenadine HCl and Pseudoephedrine HCl 24 Hour]
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended-Release Tablets
Trial: NCT05489887
Drug: Naxitamab
RxNorm normalized name: Naxitamab
DrugBank: Naxitamab (DB15965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
Trial: NCT05489887
Drug: Ceritinib
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib is an inhibitor that selectively targets the ALK tyrosine kinase
Trial: NCT04562116
Drug: Nemolizumab
RxNorm normalized name: Nemolizumab
DrugBank: Nemolizumab (DB15252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 30 mg will be administered as SC injections.
Trial: NCT06216158
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide p.o. (1.0 mg, day 1-21 of each 29-days cycle)
Trial: NCT06216158
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab s.c. (1400 mg, cycle 1: day 1, 8, 15, 22; cycles 2-3: day 1 and 15; from C4: day 1)
Trial: NCT06216158
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
Trial: NCT05968846
Drug: Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
RxNorm normalized name: povidone-iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.
Trial: NCT04700423
Drug: moxidectin (8 mg) / albendazole (400 mg)
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Trial: NCT04700423
Drug: ivermectin (200 µg/kg) / albendazole (400 mg)
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Trial: NCT04700423
Drug: ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]
RxNorm normalized name: ALBENDAZOLE 400 mg ORAL TABLET [ZENTEL]
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Trial: NCT04700423
Drug: ivermectin (200 µg/kg)
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
Trial: NCT04700423
Drug: moxidectin (8 mg)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
Trial: NCT06280209
Drug: BMN 351
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
Trial: NCT00000438
Drug: naltrexone (Revia)
RxNorm normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04961905
Drug: NVP-2002-R1+NVP-2002-R2
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP-2002-R1 1 tablet, once daily and NVP-2002-R2 1 tablet, once daily
Trial: NCT04961905
Drug: NVP-2002
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP-2002 is a combination of NVP-2002-R1 and NVP-2002_R2 NVP-2002, 1 tablet, once daily
Trial: NCT06571344
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm.
Trial: NCT05945888
Drug: BI 3000202
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 3000202
Trial: NCT05635227
Drug: Dexamethasone phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See description of arms
Trial: NCT06254066
Drug: Adebrelimab plus Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab combined with Fluzoparib in HRD-positive HR +/HER2- advanced breast cancer
Trial: NCT00002219
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002219
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00002217
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002217
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00002217
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05635227
Drug: Isotonic sodium chloride (0.9%)
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See description of arms
Trial: NCT05635227
Drug: Olanzapine 10 MG
RxNorm normalized name: olanzapine 10 MG
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
Trial: NCT05049863
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil is commercially available.